5American Thoracic Society / Centers For Disease Con trol an d Prevention(^ATS / CDC). Executive Committee. Update:Fatal and Severe Liver Injuries Associated With Rifarmpin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommen dations-United States, 2001 [J]. Am J Respir Crit Core Med, 2001,164(7): 1319-1320.
6Celli BR, Cote CG,Marin JM, et al.The body-mass index,airflow obstruction,dyspnea,and exercise capacity index in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350( 10): 1005-1012.
7Hallin R,Gudmundsson G,Suppli Ulrik C,et al.Nutritional status and long-team mortality in hospitalised patients with chronic obstr4ctive pulmonary disease (COPD) [J].Respiratory Medicine,2007,101 (9): 1954-196.
8Davidson RA.Source of funding and outcome of clinical trials [J].J Gen Internal Med,1986,1:155-158.
9CHO M K,RERO L A.The quality of drug studies published in symposium proceedings[J].Ann Intern Med, 1996,124:485-489.
